Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Apremilast 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Apremilast 30 mg BID, Placebo
B: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
C: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bimekizumab dosage regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosage regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Secukinumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosage regimen 1, Bimekizumab dosage regimen 2, Secukinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosage regimen 1, Bimekizumab dosage regimen 2

Answer: B